Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for sativex

  1. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

    NICE guideline
    Last updated
    22 March 2021
    View recommendations

    Sections for NG144

  2. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

    Technology appraisal guidance
    Discontinued

  3. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    the evidence showed benefits of THC:CBD spray (licensed product in UK: Sativex) for treating spasticity in people with multiple...

    Research recommendation
    Published
    10 February 2020